The estimated Net Worth of John Peter Mclaughlin is at least $722 Million dollars as of 21 December 2020. Mr. Mclaughlin owns over 327,934 units of PDL Biopharma Inc stock worth over $721,200,000 and over the last 17 years he sold PDLI stock worth over $855,908. In addition, he makes $370,000 as Director at PDL Biopharma Inc.
John has made over 3 trades of the PDL Biopharma Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he sold 327,934 units of PDLI stock worth $855,908 on 21 December 2020.
The largest trade he's ever made was selling 327,934 units of PDL Biopharma Inc stock on 21 December 2020 worth over $855,908. On average, John trades about 11,556 units every 125 days since 2007. As of 21 December 2020 he still owns at least 200,000 units of PDL Biopharma Inc stock.
You can see the complete history of Mr. Mclaughlin stock trades at the bottom of the page.
John Peter McLaughlin is Director of the Company. Mr. McLaughlin was our Chief Executive Officer from December 2008 until his retirement in December 2018. From November 2008 to December 2008 he served as a Senior Advisor to the Company. He was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company, from January 2000 to June 2008. From December 1997 to September 1999, Mr. McLaughlin was President of Tularik Inc., a biopharmaceutical company. From September 1987 to December 1997, Mr. McLaughlin held a number of senior management positions at Genentech, Inc., a biopharmaceutical company, including Executive Vice President and General Counsel. From January 1985 to September 1987, Mr. McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. Prior to that, Mr. McLaughlin served as counsel to various subcommittees of the United States House of Representatives, where he drafted numerous measures that became Food and Drug Administration laws. Mr. McLaughlin co-founded and served as Chairman of the Board of Eyetech Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company subsequently bought by OSI Pharmaceuticals, Inc., co-founded and served as a director of Peak Surgical, Inc., a private medical device company, until it was acquired by Medtronic in 2011, served as a director of AxoGen, Inc., a publicly-traded biopharmaceutical company until 2014, served as a director of Adverum Biotechnologies, Inc., a publicly-traded biopharmaceutical company, until 2016 and served as a director of Seattle Genetics, Inc., a publicly-traded biopharmaceutical company, until 2016. Currently, he serves on the Board of Directors of Rockwell Medical Inc. He received a B.A. from the University of Notre Dame and a J.D. from Catholic University of America.
As the Director of PDL Biopharma Inc, the total compensation of John McLaughlin at PDL Biopharma Inc is $370,000. There are 3 executives at PDL Biopharma Inc getting paid more, with Dominique Monnet having the highest compensation of $6,701,000.
John McLaughlin is 68, he's been the Director of PDL Biopharma Inc since 2018. There are no older and 7 younger executives at PDL Biopharma Inc.
John's mailing address filed with the SEC is C/O ROCKWELL MEDICAL, INC., 30142 WIXOM ROAD, WIXOM, MI, 48393.
Over the last 22 years, insiders at PDL Biopharma Inc have traded over $45,966,964 worth of PDL Biopharma Inc stock and bought 12,693,393 units worth $32,804,545 . The most active insiders traders include Point Capital L.P.O'shea Ro..., Faheem Hasnain und Laurence Jay Korn. On average, PDL Biopharma Inc executives and independent directors trade stock every 24 days with the average trade being worth of $245,074,578. The most recent stock trade was executed by Point Capital L.P.O'shea Ro... on 1 February 2021, trading 187,061 units of PDLI stock currently worth $383,475.
PDL Biopharma Inc executives and other stock owners filed with the SEC include: